ST-1898 is named as a drug or biological intervention in 3 clinical trials in our China trial register, 2 of which are recruiting. The lead sponsor is Beijing Scitech-Mq Pharmaceuticals Limited. Registered phases: Phase 1/2 and Phase 2. Conditions studied include Advanced Renal Cell Carcinoma; Differentiated Thyroid Carcinoma; Unresectable or Metastatic Melanoma.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06359847 | Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer (ClinicalTrials.gov ↗) Differentiated Thyroid Carcinoma |
Phase 2 | Recruiting |
| NCT06359860 | A Study of ST-1898 for Unresectable or Metastatic Melanoma (ClinicalTrials.gov ↗) Unresectable or Metastatic Melanoma |
Phase 1/2 | Recruiting |
| NCT06127238 | Study of ST-1898 in Advanced Renal Cell Carcinoma (ClinicalTrials.gov ↗) Advanced Renal Cell Carcinoma |
Phase 1/2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Advanced Renal Cell Carcinoma | 1 |
| Differentiated Thyroid Carcinoma | 1 |
| Unresectable or Metastatic Melanoma | 1 |
| Lead sponsor | Trials |
|---|---|
| Beijing Scitech-Mq Pharmaceuticals Limited | 3 |
| Register | ST-1898 trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ST-1898 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ST-1898 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.